These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19284288)

  • 1. Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue?
    Tai AW; Chung RT
    J Infect Dis; 2009 Apr; 199(8):1101-3. PubMed ID: 19284288
    [No Abstract]   [Full Text] [Related]  

  • 2. The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection.
    Moriguchi H; Chung RT; Contreras AM; Izumi N; Uemura T; Kobayashi M; Sato C
    Gastroenterology; 2003 Oct; 125(4):1284-6. PubMed ID: 14552320
    [No Abstract]   [Full Text] [Related]  

  • 3. Interferons and hepatitis C virus.
    Heim MH
    Swiss Med Wkly; 2012; 142():w13586. PubMed ID: 22573217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
    Ceylan B; Arslan F; Yardimci C; Fincanci M; Özgüneş N
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):493-4. PubMed ID: 24598385
    [No Abstract]   [Full Text] [Related]  

  • 5. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin.
    Boo I; Fischer AE; Johnson D; Chin R; Giourouki M; Bharadwaj M; Bowden S; Torresi J; Drummer H
    J Clin Virol; 2007 Aug; 39(4):288-94. PubMed ID: 17569577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Similar poor response in genotype 4 chronic Hepatitis C treatment with interferon and ribavirin compared with genotype 1 treatment].
    Pérez Mota A; Graus J; García Flores MA; Blanco M; Pérez-Muñoz C; Villalgordo C; Rodero R
    Rev Esp Enferm Dig; 2003 Mar; 95(3):238-9. PubMed ID: 12760714
    [No Abstract]   [Full Text] [Related]  

  • 7. [Protocol for the treatment of chronic viral hepatitis].
    Dalmi L; Gervain J; Horváth G; Hunyady B; Ibrányi E; Makara M; Pár A; Szalay F; Tornai I; Telegdy L; ;
    Orv Hetil; 2008 Jan; 149(3):129-35. PubMed ID: 18194921
    [No Abstract]   [Full Text] [Related]  

  • 8. Success of antiviral therapy in chronic hepatitis C infection relates to functional status of myeloid dendritic cells.
    Rana D; Chawla Y; Arora SK
    Indian J Med Res; 2013 Nov; 138(5):766-78. PubMed ID: 24434330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors that predict the response to interferon in patients with chronic hepatitis C: clinical management of individual patients.
    Lo Iacono O
    Rev Esp Enferm Dig; 2000 Aug; 92(8):485-94. PubMed ID: 11084816
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of interferon in the new era of hepatitis C treatments.
    Parekh PJ; Shiffman ML
    Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):649-56. PubMed ID: 24758387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection.
    Tomer S; Chawla YK; Duseja A; Arora SK
    World J Gastroenterol; 2016 Jun; 22(22):5173-82. PubMed ID: 27298560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients.
    Motawi TM; Rizk SM; Shaker OG; Mokhtar OZ
    PLoS One; 2015; 10(3):e0121524. PubMed ID: 25811198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV NS5A 2209-2248 amino acid substitutions affect serum 2,5AS activities.
    Murashima S; Kumashiro R; Ide T; Sata M
    J Hepatol; 1999 Aug; 31(2):382. PubMed ID: 10453957
    [No Abstract]   [Full Text] [Related]  

  • 15. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients.
    Baur K; Mertens JC; Schmitt J; Iwata R; Stieger B; Frei P; Seifert B; Bischoff Ferrari HA; von Eckardstein A; Müllhaupt B; Geier A;
    Antivir Ther; 2012; 17(3):541-7. PubMed ID: 22300961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
    Chung RT; Gale M; Polyak SJ; Lemon SM; Liang TJ; Hoofnagle JH
    Hepatology; 2008 Jan; 47(1):306-20. PubMed ID: 18161743
    [No Abstract]   [Full Text] [Related]  

  • 17. Interferon-λ polymorphisms and response to pegylated interferon in Iranian hepatitis C patients.
    Haj-Sheykholeslami A; Keshvari M; Sharafi H; Pouryasin A; Hemmati K; Mohammadzadehparjikolaei F
    World J Gastroenterol; 2015 Aug; 21(29):8935-42. PubMed ID: 26269684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of hepatitis C infection. A revolution should not hide another].
    Sogni P
    Presse Med; 2014 Apr; 43(4 Pt 1):339-40. PubMed ID: 24661837
    [No Abstract]   [Full Text] [Related]  

  • 19. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.
    Hu KQ; Vierling JM; Redeker AG
    J Viral Hepat; 2001 Jan; 8(1):1-18. PubMed ID: 11155147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
    Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
    Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.